Your browser doesn't support javascript.
loading
RIG-I Resists Hypoxia-Induced Immunosuppression and Dedifferentiation.
Engel, Christina; Brügmann, Grethe; Lambing, Silke; Mühlenbeck, Larissa H; Marx, Samira; Hagen, Christian; Horváth, Dorottya; Goldeck, Marion; Ludwig, Janos; Herzner, Anna-Maria; Drijfhout, Jan W; Wenzel, Daniela; Coch, Christoph; Tüting, Thomas; Schlee, Martin; Hornung, Veit; Hartmann, Gunther; Van den Boorn, Jasper G.
Afiliação
  • Engel C; Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Brügmann G; Institute for Molecular Medicine, University Hospital Bonn, Bonn, Germany.
  • Lambing S; Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Mühlenbeck LH; Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Marx S; Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Hagen C; Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Horváth D; Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Goldeck M; Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Ludwig J; Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Herzner AM; Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Drijfhout JW; Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, the Netherlands.
  • Wenzel D; Institute of Physiology I, Life and Brain Center, Medical Faculty, University of Bonn, Bonn, Germany.
  • Coch C; Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Tüting T; Department for Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.
  • Schlee M; Department of Dermatology, University of Magdeburg, Magdeburg, Germany.
  • Hornung V; Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Hartmann G; Institute for Molecular Medicine, University Hospital Bonn, Bonn, Germany.
  • Van den Boorn JG; Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universität München, München, Germany.
Cancer Immunol Res ; 5(6): 455-467, 2017 06.
Article em En | MEDLINE | ID: mdl-28468914
ABSTRACT
A hypoxic tumor microenvironment is linked to poor prognosis. It promotes tumor cell dedifferentiation and metastasis and desensitizes tumor cells to type-I IFN, chemotherapy, and irradiation. The cytoplasmic immunoreceptor retinoic acid-inducible gene-I (RIG-I) is ubiquitously expressed in tumor cells and upon activation by 5'-triphosphate RNA (3pRNA) drives the induction of type I IFN and immunogenic cell death. Here, we analyzed the impact of hypoxia on the expression of RIG-I in various human and murine tumor and nonmalignant cell types and further investigated its function in hypoxic murine melanoma. 3pRNA-inducible RIG-I-expression was reduced in hypoxic melanoma cells compared with normoxic controls, a phenomenon that depended on the hypoxia-associated transcription factor HIF1α. Still, RIG-I functionality was conserved in hypoxic melanoma cells, whereas responsiveness to recombinant type-I IFN was abolished, due to hypoxia-induced loss of type I IFN receptor expression. Likewise, RIG-I activation in hypoxic melanoma cells, but not exposure to recombinant IFNα, provoked melanocyte antigen-specific CD8+ T-cell and NK-cell attack. Scavenging of hypoxia-induced reactive oxygen species by vitamin C restored the inducible expression of RIG-I under hypoxia in vitro, boosted in vitro anti-melanoma NK- and CD8+ T-cell attack, and augmented 3pRNA antitumor efficacy in vivo These results demonstrate that RIG-I remains operational under hypoxia and that RIG-I function is largely insensitive to lower cell surface expression of the IFNα receptor. RIG-I function could be fortified under hypoxia by the combined use of 3pRNA with antioxidants. Cancer Immunol Res; 5(6); 455-67. ©2017 AACR.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores do Ácido Retinoico / Tolerância Imunológica / Melanoma / Hipóxia Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores do Ácido Retinoico / Tolerância Imunológica / Melanoma / Hipóxia Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha